Kevin Patrick Danahy Sells 20,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) insider Kevin Patrick Danahy sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $23.63, for a total transaction of $472,600.00. Following the completion of the transaction, the insider directly owned 43,298 shares in the company, valued at approximately $1,023,131.74. This represents a 31.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Kevin Patrick Danahy also recently made the following trade(s):

• On Friday, February 13th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $23.53, for a total transaction of $470,600.00.
• On Monday, February 9th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $21.45, for a total value of $429,000.00.
• On Wednesday, February 11th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $25.20, for a total transaction of $504,000.00.

Pulse Biosciences Price Performance

NASDAQ PLSE traded up $0.66 during mid-day trading on Tuesday, reaching $23.67. 303,171 shares of the stock were exchanged, compared to its average volume of 434,878. Pulse Biosciences, Inc has a one year low of $12.56 and a one year high of $26.30. The stock has a market cap of $1.60 billion, a P/E ratio of -20.95 and a beta of 1.77. The stock has a 50 day simple moving average of $15.75 and a 200-day simple moving average of $15.90.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on PLSE shares. Mizuho set a $30.00 price target on shares of Pulse Biosciences in a research report on Friday, February 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $26.00.

Institutional Investors Weigh In On Pulse Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of PLSE. Bank of America Corp DE grew its stake in Pulse Biosciences by 2.7% during the third quarter. Bank of America Corp DE now owns 804,960 shares of the company’s stock valued at $14,248,000 after acquiring an additional 21,424 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Pulse Biosciences by 7.2% in the second quarter. Geode Capital Management LLC now owns 499,464 shares of the company’s stock worth $7,538,000 after purchasing an additional 33,744 shares during the period. State Street Corp raised its position in shares of Pulse Biosciences by 6.0% in the fourth quarter. State Street Corp now owns 447,067 shares of the company’s stock worth $6,138,000 after buying an additional 25,187 shares in the last quarter. Brooklyn Investment Group boosted its position in shares of Pulse Biosciences by 330.7% during the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock valued at $1,844,000 after acquiring an additional 100,081 shares during the last quarter. Finally, Portolan Capital Management LLC bought a new stake in Pulse Biosciences during the third quarter valued at approximately $1,809,000. 76.95% of the stock is owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.